A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection

Nicholas J. Barrows, Rafael K. Campos, Steven T. Powell, K. Reddisiva Prasanth, Geraldine Schott-Lerner, Ruben Soto-Acosta, Gaddiel Galarza-Muñoz, Erica L. McGrath, Rheanna Urrabaz-Garza, Junling Gao, Ping Wu, Ramkumar Menon, George Saade, Ildefonso Fernandez-Salas, Shannan L. Rossi, Nikos Vasilakis, Andrew Routh, Shelton S. Bradrick, Mariano A. Garcia-Blanco

Research output: Contribution to journalArticlepeer-review

260 Scopus citations

Abstract

Currently there are no approved vaccines or specific therapies to prevent or treat Zika virus (ZIKV) infection. We interrogated a library of FDA-approved drugs for their ability to block infection of human HuH-7 cells by a newly isolated ZIKV strain (ZIKV MEX_I_7). More than 20 out of 774 tested compounds decreased ZIKV infection in our in vitro screening assay. Selected compounds were further validated for inhibition of ZIKV infection in human cervical, placental, and neural stem cell lines, as well as primary human amnion cells. Established anti-flaviviral drugs (e.g., bortezomib and mycophenolic acid) and others that had no previously known antiviral activity (e.g., daptomycin) were identified as inhibitors of ZIKV infection. Several drugs reduced ZIKV infection across multiple cell types. This study identifies drugs that could be tested in clinical studies of ZIKV infection and provides a resource of small molecules to study ZIKV pathogenesis.

Original languageEnglish (US)
Pages (from-to)259-270
Number of pages12
JournalCell Host and Microbe
Volume20
Issue number2
DOIs
StatePublished - Aug 10 2016

ASJC Scopus subject areas

  • Parasitology
  • Microbiology
  • Virology

Fingerprint Dive into the research topics of 'A Screen of FDA-Approved Drugs for Inhibitors of Zika Virus Infection'. Together they form a unique fingerprint.

Cite this